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Abstract 
For long, apoptotic cells have been considered as intrinsically tolerogenic or unable to elicit 
immune responses specific for dead cell-associated antigens. However, multiple stimuli can trigger 
a functionally peculiar type of apoptotic demise that does not go unnoticed by the adaptive arm of 
the immune system, which we named “immunogenic cell death” (ICD). ICD is preceded or 
accompanied by the emission of a series of immunostimulatory damage-associated molecular 
patterns (DAMPs) in a precise spatiotemporal configuration. Several anticancer agents that have 
been successfully employed in the clinic for decades, including various chemotherapeutics and 
radiotherapy, can elicit ICD. Moreover, defects in the components that underlie the capacity of the 
immune system to perceive cell death as immunogenic negatively influence disease outcome among 
cancer patients treated with ICD inducers. Thus, ICD has profound clinical and therapeutic 
implications. Unfortunately, the gold-standard approach to detect ICD relies on vaccination 
experiments involving immunocompetent murine models and syngeneic cancer cells, an approach 
that is incompatible with large screening campaigns. Here, we outline strategies conceived to detect 
surrogate markers of ICD in vitro and to screen large chemical libraries for putative ICD inducers, 
based on a high-content, high-throughput platform that we recently developed. Such platform 
allows for the detection of multiple DAMPs, like cell surface-exposed calreticulin, extracellular 
ATP and high mobility group box 1 (HMGB1), and/or the processes that underlie their emission, 
such as endoplasmic reticulum stress, autophagy and necrotic plasma membrane permeabilization. 
We surmise that this technology will facilitate the development of next-generation anticancer 
regimens, which kill malignant cells and simultaneously convert them into a cancer-specific 
therapeutic vaccine. 
Introduction 
Cell death can be classified based on several parameters, including morphological manifestations, 
biochemical features, kinetic considerations and functional outcomes.1-7 This said, how cell death 
has been investigated and conceived since its pristine descriptions (dating back to the mid-19th 
century)8 has obviously evolved along with the technological advances that have been made 
throughout the last one and a half centuries.9,10 Thus, morphology-based classifications postulating 
the existence of three cell death subroutines (i.e., type I, type II and type III cell death)2,11-14 have 
been progressively abandoned in favor of definitions that rely on objectively quantifiable functional 
features.3,15-19 Alongside, the long-standing conception according to which distinct types of cell 
death like apoptosis and necrosis would constitute mutually exclusive and diametrically opposed 
entities has been refuted. In particular, throughout the past two decades it has become clear that: (1) 
apoptosis is not the sole type of regulated cell death that contributes to (post-)embryonic 
development and adult tissue homeostasis;20 (2) similar to apoptosis, necrosis can occur in a 
regulated fashion, i.e., it can involve a genetically encoded molecular machinery;4,5,21 (3) similar to 
their necrotic counterparts, apoptotic cells can sometimes be detected by the immune system and 
elicit an adaptive immune response specific for dead cell-associated antigens.6,7,22,23 Thus, although 
apoptosis as a physiological process involved in (post-)embryonic development and tissue 
homeostasis invariably fails to engage the adaptive branch of the immune system,24,25 specific 
stimuli can promote an immunogenic variant of regulated cell death that manifests with both 
morphological and biochemical features of apoptosis.2,3,6 Of note, defects in the clearance of 
apoptotic cells by professional phagocytes have been associated with autoimmune conditions such 
as systemic lupus erythematosus (SLE) and chronic inflammation.26,27 However, it remains unclear 
whether this reflects the immunogenic potential of intact apoptotic corpses or the insurgence of 
secondary necrosis. 
Back in 2005, we were the first to report the unexpected finding that murine colorectal carcinoma 
CT26 cells as well as murine fibrosarcoma MCA205 cells exposed to a lethal dose of doxorubicin 
in vitro are capable of vaccinating syngeneic mice against a subsequent challenge with living cells 
of the same type.22 We dubbed such a functionally peculiar variant of cellular demise, manifesting 
with an apoptotic morphology and depending on the activity of apoptotic caspases, “immunogenic 
cell death” (ICD).22 It turned out that the unsuspected ability of doxorubicin (an anthracycline 
employed for the treatment of various carcinomas) to trigger ICD as a standalone intervention, 
hence converting dying cancer cells into a vaccine that is efficient in the absence of adjuvants, is 
shared by a relatively restricted set of lethal triggers.28-33 These include, but perhaps are not limited 
to, mitoxantrone and epirubicin (two other anthracyclines currently used in the clinic),34-37 
bleomycin (a glycopeptide antibiotic endowed with antineoplastic properties),38 oxaliplatin (a 
platinum derivative generally employed against colorectal carcinoma),39-42 cyclophosphamide (an 
alkylating agent approved for the treatment of neoplastic and autoimmune conditions),43-48 
etoposide (a topoisomerase inhibitor currently used for the treatment of several neoplasms) 
combined with the chemical inhibitor of glycolysis 2-deoxyglucose,49,50 patupilone (a microtubular 
inhibitor that has not yet been approved for use in humans),51-53 septacidin (an antifungal antibiotic 
produced by Streptomyces fibriatus)54,55 specific forms of radiation therapy,34,56-64 photodynamic 
therapy (a clinically approved anticancer intervention that involves the administration of a 
photosensitizing agent followed by light irradiation),65-73 high hydrostatic pressure,74 multiple 
oncolytic viruses,75-83 replication-defective viral vectors encoding a potentially cytotoxic product 
(e.g., thymidine kinase from herpes simplex virus type I, HSV-1) combined with viruses expressing 
an immunostimulatory molecule (e.g., fms-related tyrosine kinase 3 ligand, FLT3LG),84 the 
clinically employed proteasomal inhibitor bortezomib,85-87 shikonin (a component of Chinese herbal 
medicine),88 a monoclonal antibody specific for the epidermal growth factor receptor (EGFR),89 
capsaicin (a neurotoxic derivative of homovanillic acid found in chili peppers),90,91 and perhaps the 
n3-polyunsaturated fatty acid docosahexaenoic acid,92 as well as the transgene-driven expression of 
SMAC mimetics.93,94 In addition, some interventions are capable of converting non-immunogenic 
instances of cell death into bona fide ICD. These maneuvers include the administration of cardiac 
glycosides, which are particularly powerful in this respect as they promote per se all major 
manifestations of ICD (see below),95-97 or zoledronic acid (a bisphosphonate currently approved to 
treat osteoporosis and to prevent skeletal fractures in cancer patients with bone metastases),98,99 as 
well as the provision of co-stimulatory signals via CD40.100 This said, it should be kept in mind that 
the capacity of a given agent to cause ICD or exacerbate the immunogenicity of apoptosis cannot be 
predicted yet from its structural or chemical properties, since molecules as similar to each other as 
oxaliplatin and cisplatin do not share this functional profile.39,40 
The notion that apoptotic cancer cells do not always go undetected by the immune system has 
profound clinical repercussions.101 First, it implies that the immune system, at least under specific 
circumstances, can mount an adaptive immune response against (self) malignant cells, hence 
mediating antineoplastic effects or contributing to the therapeutic activity of conventional 
anticancer regimens. This concept represents the theoretical foundation of modern tumor 
immunology and anticancer immunotherapy.22,102,103 As a matter of fact, many chemotherapeutics 
that have been successfully used in the clinic throughout the past century have recently been 
discovered to mediate off-target immunostimulatory effects, ICD being one of the underlying 
mechanisms (though not the sole).104-106 Second, it implies that a large number of parameters 
reflecting the immunological competence of the host, including the type, quantity and localization 
of tumor-infiltrating lymphoid and myeloid cells,107-113 the amount of blood-borne memory T cells 
that are able to recognize antigens associated with apoptotic cancer cells,114 the circulating levels of 
various ICD-associated biomarkers, including the non-histone chromatin-binding protein high 
mobility group box 1 (HMGB1),46,115-117 as well as genetic polymorphisms affecting virtually all 
facets of the immune response,41,108,118,119 may be endowed with a robust prognostic or predictive 
value. This notion has already been demonstrated in several ICD-related clinical scenarios. Thus, 
the relative abundance of tumor-infiltrating CD8+ cytotoxic T lymphocytes (CTLs) and 
CD4+CD25+FOXP3+ regulatory T cells reportedly predicts the propensity of breast carcinoma 
patients to benefit from anthracycline- or oxaliplatin-based chemotherapy, respectively.52,120 Along 
similar lines, single nucleotide polymorphisms in the genes coding for ICD-relevant receptors such 
as Toll-like receptor 4 (TLR4) and purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) 
have been shown to influence disease outcome among breast carcinoma patients treated with 
anthracycline-based chemotherapy.41,119 Taken together, these observations demonstrate that the 
induction of ICD is a therapeutically relevant objective, calling for the identification of novel ICD 
inducers and molecules that improve the immunogenicity of conventional variants of apoptosis. 
After summarizing the main molecular and cellular determinants that underlie ICD, we discuss the 
assays that are currently available for the detection of surrogate ICD markers and how these 
methods can be combined into a platform that is compatible with high-content, high-throughput 
applications. We surmise that this methodological approach will accelerate the discovery and 
development of therapeutic regimens that kill malignant cells in an immunogenic fashion. 
 
Immunogenic cell death signaling 
According to current models, ICD relies on the ability of specific stimuli to kill cells while 
provoking the spatiotemporally coordinated emission of immunogenic signals.7,121-129 Such signals 
are conveyed by damage-associated molecular patterns (DAMPs), i.e., molecules that are not 
accessible by the immune system in physiological conditions but are released or exposed on the 
outer leaflet of the plasma membrane during cytoprotective stress responses or upon cell 
death.103,130-133 Similar to their microbial counterparts, many (but not all) DAMPs exert robust 
immunostimulatory effects upon binding to pattern recognition receptors (PRRs) expressed by 
immune cells.121 So far, three DAMPs have been attributed a key role in the immunogenic potential 
of virtually all ICD inducers: the endoplasmic reticulum (ER) chaperone calreticulin 
(CALR),34,65,126,134-136 ATP,66,124,137-143 and HMGB1.41,46,115,116,144-147 In addition, many DAMPs 
have been shown to contribute to the immunogenicity of cell death in a limited amount of 
experimental scenarios. These include immunostimulatory cytokines like interferon α (IFNα),148,149 
various chaperones of the heat-shock protein (HSP) family, notably heat shock 70kDa protein 1A 
(HSPA1A, best known as HSP70) and heat shock protein 90kDa alpha (cytosolic), class A member 
1 (HSP90AA1, best known as HSP90),65,71,85,90,145,150-153 sphingomyelin metabolites (e.g., ceramide 
and sphingosine-1-phosphate),154 a plethora of mitochondrial products (e.g., mitochondrial DNA, 
N-formylated peptides, cardiolipin),155-157 cytosolic components like urate and F-actin,158-161 as well 
as products of the breakdown of the extracellular matrix (e.g., hyaluronan fragments).162,163 
CALR gets exposed on the cell surface early in the course of ICD, i.e., before the apoptosis-
associated shuffling of phosphatidylserine between the inner and outer leaflet of the plasma 
membrane.34,164,165 The molecular mechanisms underlying this ICD hallmark have been dissected in 
detail and appear to involve three distinct signaling modules: (1) an ER stress module centered 
around the phosphorylation of eukaryotic translation initiation factor 2A (EIF2A) and the resultant 
arrest in protein synthesis; (2) an apoptotic module involving the activation of caspase-8 and the 
consequent cleavage of B-cell receptor-associated protein 31 (BCAP31) as well as the pro-apoptotic 
Bcl-2 family members BCL2-associated X protein (BAX) and BCL2-antagonist/killer 1 (BAK1); 
and (3) an exocytosis module requiring the actin cytoskeleton as well as vesicle-associated 
membrane protein 1 (VAMP1) and synaptosomal-associated protein, 25kDa (SNAP25), two 
proteins involved in intracellular vesicular trafficking.36 Moreover, in some (but not all) models of 
ICD,67 CALR obligatorily translocates to the cell surface together with another ER chaperone, 
protein disulfide isomerase family A, member 3 (PDIA3).36,37 Upon binding to low density 
lipoprotein receptor-related protein 1 (LRP1, also known as CD91), membrane-exposed CALR 
delivers a major phagocytic signal to professional antigen-presenting cells (APCs) such as dendritic 
cells, de facto improving their capacity to take up dead cells and their corpses.66,91,166-173 
Interestingly, the phagocytosis-stimulatory effects of CALR is robustly counterbalanced by CD47, 
which is highly expressed by a large panel of solid and hematopoietic tumors.166 This latter 
observation suggests that various neoplasms benefit from avoiding the effects of CALR exposure, 
perhaps as this prevents the elicitation of an adaptive immune response against the malignant cells 
that “physiologically” succumb in the course of oncogenesis and tumor progression. Alternatively, 
the phagocytosis-inhibitory activity of CD47 may confer tumors with an advantage by increasing 
the local availability of macromolecules derived from the spontaneous demise (and degradation) of 
some of their cellular constituents. This possibility has not yet experimentally addressed. 
The ICD-associated release of ATP proceeds through a complex mechanism that involves (1) the 
apparent relocalization of vesicular ATP stores from lysosomes to autolysosomes; (2) the 
redistribution of lysosomal-associated membrane protein 1 (LAMP1) to the plasma membrane; (3) 
Rho-associated, coiled-coil containing protein kinase 1 (ROCK1)-mediated, myosin II-dependent 
cellular blebbing; and (4) the opening of pannexin 1 (PANX1) channels, 4 processes that rely on 
caspases.140,142,174 In a vast majority of models, the secretion of ATP by cells exposed to ICD 
inducers requires an intact autophagic machinery.83,138,139,175 In these settings, the genetic or 
pharmacological inhibition of autophagy limits ATP release by cells succumbing to ICD and hence 
negatively influences their ability to elicit an adaptive immune response upon inoculation in 
immunocompetent syngeneic mice.60,138,139 Along similar lines, the chemical inducer of autophagy 
STF-62247 increases the immunostimulatory potential of ICD as triggered by chlorin-e6-based 
photodynamic therapy (MK, unpublished observations). However, this does not seem to apply to all 
ICD inducers.68 Thus, the ability of hypericin-based photodynamic therapy to induce the secretion 
of ATP does not appear to change in autophagy-deficient versus autophagy-proficient cells.68,70,176 
Moreover, the former respond to hypericin-based photodynamic therapy by exposing higher 
amounts of CALR on the plasma membrane than the latter, hence exhibiting a superior 
immunogenic potential.68,70,176 Possibly, this reflects the incapacity of autophagy-deficient cells to 
clear oxidized proteins, resulting in an aggravation of the ER stress response that underlies CALR 
exposure in the course of ICD.68,70,176 Irrespective of these variations, extracellular ATP operates as 
a strong chemoattractant and promotes not only the recruitment of immune cells to sites of ICD, but 
also their differentiation, an effect that depends on purinergic receptor P2Y, G-protein coupled, 2 
(P2RY2).141,177-179 Moreover, extracellular ATP promotes the activation of the NLR family, pyrin 
domain containing 3 (NLRP3) inflammasome in APCs, hence stimulating the processing and 
release of interleukin (IL)-1β and IL-18.119,180-189 In line with this notion, the immunogenic potential 
of cells succumbing to ICD can be significantly reduced by pharmacological or genetic 
interventions that limit the availability of ATP in the pericellular space, such as the administration 
of recombinant apyrase (an ATP-degrading enzyme) or the transfection-enforced overexpression of 
ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, best known as CD39), which 
converts ATP into ADP and AMP.190 Intriguingly, CD39 and 5'-nucleotidase, ecto (NT5E, best 
known as CD73), which transforms AMP into adenosine, are often overexpressed by malignant 
tissues. This reflects the advantage conferred to cancer cells by the conversion of extracellular ATP, 
which promotes immunosurveillance, into adenosine, which exerts potent immunosuppressive 
effects.191-197 Of note, autophagy is also important for the perception of cell death as immunogenic 
because it contributes to several aspects of cellular immune responses, including the differentiation, 
survival and activation of myeloid and lymphoid cells.198-200 
The release of HMGB1 from cells succumbing to ICD requires the permeabilization of both the 
nuclear and plasma membranes, de facto constituting a post-mortem event.3,41 Although autophagy 
has been proposed to contribute to the release of HMGB1 from dying cells, at least under some 
circumstances,201 the molecular machinery that underlies this crucial manifestation of ICD has not 
yet been elucidated in detail. This said, extracellular HMGB1 is well known to mediate robust pro-
inflammatory effects upon binding to several receptors on the surface of immune cells, including 
TLR2, TLR4 and advanced glycosylation end product-specific receptor (AGER, best known as 
RAGE).202-210 Moreover, extracellular HMGB1 reportedly exerts a chemotactic activity by forming 
a complex with chemokine (C-X-C motif) ligand 12 (CXCL12) that signals via chemokine (C-X-C 
motif) receptor 4 (CXCR4).211 Finally, at least under some circumstances, endogenous HMGB1 
appears to promote autophagy by interfering with the mutually inhibitory interaction between the 
central autophagic regulator beclin 1 (BECN1) and the anti-apoptotic protein B-cell 
CLL/lymphoma 2 (BCL2).212-214 It is therefore tempting to speculate, yet remains to be formally 
demonstrated, that the nuclear release of HMGB1 may contribute to the autophagic response of 
cells succumbing to ICD inducers. Of note, the biological activity of extracellular HMGB1 appears 
to be regulated by its redox state.215-221 Moreover, HMGB1 binds not only to TLR2, TLR4 and 
RAGE, but also to hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3), hence 
mediating immunosuppressive (as opposed to immunostimulatory) effects.222-224 Taken together, 
these observations suggest that the biological activity of HMGB1 exhibits a consistent-degree of 
context-dependency. Nonetheless, HMGB1-deficient malignant cells exposed to ICD inducers fail 
to elicit adaptive immune responses upon inoculation into immunocompetent syngeneic mice, a 
defect that can be corrected by the co-administration of synthetic TLR4 ligands.225-228 Together with 
the notion that Tlr4-/- mice fail to perceive anthracycline-treated syngeneic cells as 
immunogenic,41,229 this observation demonstrates the importance of the HMGB1-TLR4 signaling 
axis for ICD. 
In summary, the spatiotemporally coordinated emission of specific DAMPs promotes the 
recruitment of APCs to sites of ongoing ICD, their ability to take up dead cell-derived particulate 
material, as well as their capacity to prime an adaptive immune response.6 This generally proceeds 
in two phases, involving the sequential recruitment and activation of IL-17-secreting γδ T cells and 
αβ CTLs.31,230 The latter not only mediate direct antineoplastic effects, mostly by secreting 
interferon γ (IFNγ) and via the granzyme-perforin pathway, but also underlie the establishment of 
protective immunological memory (Figure 1).231  
Gold-standard methods to monitor ICD 
As it stands, the gold-standard approach to evaluate the ability of a specific stimulus to cause bona 
fide ICD relies on vaccination assays.6,22,30 In this setting, malignant cells are exposed in vitro to the 
lethal stimulus of choice, thoroughly washed (to remove the stimulus), resuspended in an adequate 
volume of PBS, and then inoculated subcutaneously into the flank of immunocompetent syngeneic 
mice. One week later, living cells of the same type are introduced subcutaneously into the opposite 
flank, and mice are routinely monitored for the appearance of a palpable neoplastic lesion (Figure 
2A). The proportion of mice that do not develop subcutaneous tumors reflects the degree of 
immunogenicity of cell death as induced by the lethal trigger under evaluation. As a note, murine 
cells succumbing to prototypic inducers of ICD such as doxorubicin and mitoxantrone effectively 
vaccinate 80% of mice.34,95,232 
As a confirmatory assay, putative ICD inducers can be assessed for their ability to mediate immune 
system-dependent therapeutic effects against established neoplastic lesions.6,34,233 In this scenario, 
grafted, genetically-driven or chemically-induced subcutaneous or orthotopic tumors are established 
in both immunocompetent and immunodeficient mice. Malignant lesions are then allowed to 
progress until a pre-determined size or time point, beyond which tumor-bearing mice are treated 
with the compound under evaluation (Figure 2B). In this experimental setup, bona fide ICD 
inducers mediate optimal therapeutic effects in immunocompetent, but not in immunodeficient, 
mice.34,41,95,119,233 Importantly, this latter approach is suitable to validate the results of vaccination 
experiments but cannot be employed alone to determine the capacity of a specific intervention to 
cause ICD. Indeed, even the activity of antineoplastic regimens that fail to render dying cells 
immunogenic but induce other immunostimulatory effects is negatively affected by the absence of a 
functional immune system.104,105 Among other molecules, this applies to the microtubular inhibitor 
paclitaxel and the nucleoside analogue gemcitabine.104,105 
The main drawbacks of these types of assay relate to the use of rodents and syngeneic tumor 
models: the need for a tightly controlled sterile facility (which is mandatory for working with 
immunodeficient animals), prolonged times for the establishment/growth of neoplastic lesions, and 
significant costs. Moreover, vaccination and therapeutic tests for the detection of ICD are limited by 
the relatively restricted number of syngeneic tumor models that are currently available. Thus, 
although they constitute the gold-standard approach for the detection of ICD, vaccination assays 
relying on immunocompetent mice and syngeneic cancer cells are intrinsically incompatible with 
large screening campaigns. To circumvent this issue, various techniques that allow for the detection 
of one or more ICD manifestations in vitro and in vivo have been developed.6,234 Monitoring the 
immunostimulatory activity of lead compounds (be it linked to the induction of ICD or reflecting 
other mechanisms) early in the drug discovery pipeline may indeed speed up significantly the 
development of novel anticancer agents.104  
Detection of surrogate ICD biomarkers 
A relatively ample panel of ICD-associated phenomena can be monitored in vitro to obtain insights 
into the ability of a specific intervention to provoke ICD (Table 1). 
Cell death. By definition, ICD inducers must be cytotoxic and provoke cell death above a minimal 
threshold level. Cancer cells emit indeed a wide panel of DAMPs in response to non-lethal 
perturbations of homeostasis. However, such DAMPs differ in both qualitative and quantitative 
terms from those emitted by cells of the same type dying in response to the same stimulus applied 
with a lethal intensity/duration. Living cells are less likely to be taken up by APCs and ignite an 
adaptive immune response than their dying counterparts. Moreover, if the fraction of dying cells is 
excessively low, neoplastic lesions develop at the vaccination site and protective immunity cannot 
be established.34,95 Thus, agents that stimulate all the key manifestations of ICD including CALR 
exposure, ATP secretion and HMGB1 release, but fail to exert robust cytotoxic effects cannot be 
considered as authentic ICD inducers. This is the case of cardiac glycosides including digoxin and 
digitoxin, which nonetheless are powerful at converting non-immunogenic instances of cell death 
into bona fide ICD, hence operating as potent immune adjuvant.95-97,235 
Several assays are commercially available to monitor cell death-associated parameters, the most 
reliable indicator of cell death being end-stage plasma membrane permeabilization.9,236 This can be 
conveniently monitored by so-called exclusion dyes like the DNA-binding chemicals propidium 
iodide (PI) and 4',6-diamidino-2-phenylindole (DAPI), which only accumulate in cells with 
permeabilized plasma membranes. PI and DAPI can be conveniently detected by flow cytometry or 
fluorescence microscopy (absorption/emission peaks: 535/617 and 358/461 nm, respectively). On 
flow cytometry, both PI and DAPI can be combined with fluorescence variants of the protein 
annexin A5 (ANXA5), permitting the detection of phosphatidylserine exposure,9,237,238 as well as 
with 3,3’-dihexyloxacarbocyanine iodide (DiOC6(3), absorption/emission peaks: 482/504 nm), 
allowing for the quantification of mitochondrial transmembrane potential (Δψm).239-241 The 
externalization of phosphatidylserine (a phospholipid normally restricted to the inner leaflet of the 
plasma membrane) accompanies indeed multiple (though not all) instances of apoptotic cell 
death,16,242-245 while the permanent dissipation of the Δψm as a result of mitochondrial outer 
membrane permeabilization (MOMP) constitutes one of the major hallmarks of mitochondrial 
apoptosis.17,18,246,247 Of note, DiOC6(3) is not compatible with fixation, but other Δψm-sensitive 
probes that exist are, including chloromethyltetramethylrosamine (absorption/emission peaks: 
554/576 nm).248 MOMP is accompanied by the massive activation of caspase-9 and -3, while 
caspase-8 is required for ICD upstream of MOMP. The activation of caspases can be documented 
by flow cytometry or fluorescence microscopy, either upon the immunostaining of cells with 
monoclonal antibodies specific for active caspase fragments, or with cell-permeant caspase 
substrates that become fluorescent upon cleavage.9,249,250 Alternatively, caspase activation can be 
detected in a semi-quantitative manner by immunoblotting, with antibodies specific for caspases 
(which are themselves activated by cleavage) or their substrates.250,251  
As MOMP ensues the assembly of BAX/BAK1-containing oligomers across the outer 
mitochondrial membrane, the process can also be monitored by means of green fluorescent protein 
(GFP)-BAX chimeras (GFP absorption/emission peaks: 395/509 nm). In this setting, the 
relocalization of BAX to mitochondria can be followed by fluorescence microscopy as a shift in 
GFP fluorescence from a diffuse to a punctate or network-like pattern.40,252 Finally, one of the major 
morphological modifications of apoptosis (and hence of ICD) is nuclear condensation 
(pyknosis).1,2,95 Also this process can be conveniently monitored by fluorescence microscopy, either 
in cells that constitutively express a GFP- or red fluorescent protein (RFP)-tagged variant of histone 
2B (RFP-H2B, absorption/emission peaks: 584/607 nm) or upon fixation and staining with the 
chromatinophilic dye Hoechst 33342 (absorption/emission peaks: 361/461 nm).40,95,235 
 
CALR exposure. Several assays are available to directly monitor the ICD-associated translocation 
of CALR on the outer leaflet of the plasma membrane. For instance, this can be achieved on flow 
cytometry, by staining non-permeabilized cells with a CALR-specific antibody, or in cells that 
stably express a CALR-HaloTag™ fusion protein.40,95 In the latter scenario, the HaloTag™ label 
can be visualized by a cell-impermeant fluorescent chemical, resulting in the specific detection of 
the CALR molecules that are effectively accessible for ligand binding from the extracellular 
microenvironment.40,95 In both cases, it is imperative to remove from the analysis dead (PI+ or 
DAPI+) cells, as the permeabilized plasma membrane allows both the CALR-specific antibody and 
the normally cell-impermeant HaloTag™ ligand to access intracellular CALR.34,40 Alternatively, 
CALR exposure can be monitored upon the biotinylation of cell surface proteins (which must be 
performed in pre-apoptotic conditions, when plasma membranes are intact, to avoid false-positive 
results owing to intracellular CALR), followed by streptavidin-mediated precipitation, and 
detection by immunoblotting,34,66,253 or by fluorescence microscopy, in cells that constitutively 
express a CALR-GFP fusion construct. For the sake of precision, it should be noted that the latter 
system does not detect CALR-GFP exposure in itself, but the ER perinuclear clustering that 
invariably accompanies exposure.20,232 We have also successfully employed a PDIA3-specific 
antibody and flow cytometry as well as PDIA3-GFP-expressing cells and fluorescence microscopy 
to (indirectly) assess CALR exposure in the course of ICD, as in our models PDIA3 invariably co-
translocates with CALR on the surface of cells exposed to ICD inducers.36,37,95 However, this does 
not apply to all experimental settings,66,67 implying that the PDIA3-GFP fusion is a useful 
confirmatory tool but cannot be employed as a standalone means to identify all instances of ICD. 
In some instances, it may be important to monitor CALR exposure along with the proficiency of the 
ER stress response. This may indeed allow for the identification of defects in the signaling pathway 
that leads to the translocation of CALR to the outer leaflet of the plasma membrane. Several assays 
are currently available for the detection of the different arms of the ER stress response.136,254-256 For 
instance, the phosphorylation state of EIF2A and/or of the major EIF2A kinases, including EIF2A 
kinase 1 (EIF2AK1, best known as HRI),257 EIF2AK2 (best known as PKR),258 and EIF2AK3 (best 
known as PERK),259-261 can be assessed by immunoblotting, flow cytometry or 
immunofluorescence microscopy with phosphoneoepitope-specific antibodies.260 The splicing 
status of X-box binding protein 1 (XBP1) mRNA, reflecting the activation of the ER stress sensor 
endoplasmic reticulum to nucleus signaling 1 (ERN1, best known as IRE1α), can be monitored by 
quantitative real-time RT-PCR,262 as well as by flow cytometry or fluorescence microscopy, either 
in cells that express a fluorescently-tagged version of XBP1263 or upon the administration of a self-
quenched RNA probe that can be cleaved by IRE1α.264 Finally, the nuclear redistribution of 
activating transcription factor 6 (ATF6) can be easily evaluated by fluorescence microscopy in cells 
that constitutively express GFP- or RFP-tagged variants of ATF6.52 As an alternative, ER stress can 
be indirectly monitored upon the formation of GTPase activating protein (SH3 domain) binding 
protein 1 (G3BP1)-containing granules in cells genetically modified to express a G3BP1-GFP 
fusion.40,265 This said, G3BP1 appears to redistribute to granules in response to a wide panel of 
stressful conditions that are not limited to specific perturbations of reticular homeostasis. Thus, 
monitoring G3BP1 aggregation can be useful to determine whether cells mount a stress response to 
a putative inducer of ICD, yet cannot be employed to formally imply the ER in this process. 
 
ATP secretion. The ICD-associated secretion of ATP can be monitored by two complementary 
approaches: directly, by quantification of extracellular ATP,137,180 or indirectly, by the assessment 
of residual intracellular ATP.137,139 The most employed method currently available for the 
quantification of ATP levels relies on the ability of eukaryotic luciferases to produce light while 
oxidizing D-(-)-luciferin (which must be added exogenously) in a ATP-dependent manner.266,267 
This can be applied to culture supernatants as well as to cell lysates, and hence is compatible with 
both the direct and indirect assessment of ATP secretion in the course of ICD. The vesicular pool of 
ATP can also be visualized by fluorescence microscopy upon staining cells with the ATP-binding 
fluorochrome quinacrine (absorption/emission peaks: 436/525 nm).268 Alternatively, intracellular 
ATP can be monitored in living cells by a fluorescence resonance energy transfer (FRET)-based 
assay involving a yellow fluorescent protein-cyan fluorescent protein (YFP-CFP) fusion containing 
a domain that changes its conformation upon ATP binding, hence shifting the spectral properties of 
the probe.269 
In some settings, it may be relevant to monitor the autophagic response that generally precedes and 
is required for ICD-associated ATP release. This can be achieved by a wide panel of techniques, 
whose detailed discussion goes largely beyond the scope of this set of recommendations.15,270,271 
This said, one of the most convenient approaches to obtain insights into the autophagic response of 
cells exposed to homeostatic perturbations relies on the use of a GFP- or RFP-tagged variant of 
microtubule-associated protein 1 light chain 3 (MAP1LC3, best known as LC3).272 In the course of 
autophagy, LC3 gets conjugated to phosphatidylethanolamine, hence acquiring the ability to 
accumulate into forming autophagosomes.273,274 In line with this notion, GFP-LC3 redistributes 
from a diffuse to a punctate pattern in cells mounting an autophagic response, a phenomenon that 
can readily be monitored by fluorescence microscopy.  
 
HMGB1 release. Similar to the secretion of ATP, the release of HMGB1 in the supernatant of cells 
undergoing ICD can be monitored directly or indirectly, as a function of residual intracellular 
HMGB1.41,207,275 The former approach relies on the immunoblotting-based assessment of HGMB1 
in concentrated cell supernatants, or (most often) on commercially available enzyme-linked 
immunosorbent assay (ELISA) kits specific for human or murine HMGB1. These kits generally 
allow for the precise quantification of HMGB1 concentrations in a wide panel of biological 
specimens, including culture supernatants, serum samples and interstitial fluids, yet may be 
relatively expensive for use in large-scale screening campaigns.95,147,275 Alternatively, HMGB1 
release can be assessed by fluorescence microscopy in cells expressing a GFP-tagged variant of 
HMGB1, as the loss of colocalization between the GFP signal and a nuclear staining (e.g., Hoechst 
33342, H2B-RFP).275 This said, the precise quantification of HMGB1 variants exhibiting 
differential redox states requires mass spectroscopy.276 
 
High-content, high-throughput platform. Cell death that is not accompanied by CALR exposure, 
ATP secretion and HMGB1 release is generally not perceived as immunogenic.34,41,119 In other 
words, the absence of only one such ICD-associated events often entails a consistent decrease in the 
immunogenicity of cell death, if not its total loss. This implies that the ability of a given 
intervention to promote ICD can be inferred in vitro only upon the concurrent evaluation of all ICD 
hallmarks. Indeed, cells succumbing to homeostatic perturbations that stimulate ATP secretion and 
HMGB1 release but not CALR exposure, such as the administration of cisplatin, fail to elicit 
adaptive immune responses upon inoculation into immunocompetent mice.34,39,40 This said, a 
platform that would allow for the simultaneous detection of cell death, CALR exposure, ATP 
secretion and HMGB1 release in the context of large screening campaigns was missing. To 
circumvent this obstacle to the identification of novel, perhaps clinically relevant bona fide inducers 
of ICD, we recently developed a robotized cell biology platform that allows for entirely automated 
compound handling and multiplex read-out capability (including fluorescence microscopy, flow 
cytometry and bioluminescence detection) in sterile conditions. We then designed fully automated 
workflows based on various combinations of the assays described above and including appropriate 
procedures for data handling/normalization and statistical analysis. This approach is compatible 
with the high-content, high-throughput screening of large chemical libraries, returning a cumulative 
score that represents the ability of a specific compound to promote the four tenets of ICD. 
Importantly, this integrated platform does not abolish the need to evaluate putative ICD inducers for 
their capacity to elicit protective anticancer immune responses in gold-standard vaccination assays. 
Nonetheless, it allows for the relatively straightforward identification of candidate molecules. By 
means of this approach, septacidin has been identified as a bona fide ICD inducer.232 Moreover, 
cardiac glycosides were found to robustly improve the immunogenic potential of cell death.95-97,235 
We expect this platform not only to allow for the discovery of other ICD inducers, but also to 
facilitate the understanding of the molecular pathways that underlie ICD and how these can be 
modulated for therapeutic purposes. 
Concluding remarks and future directions 
As described above, the simultaneous detection of cell death, CALR exposure, ATP secretion and 
HMGB1 release by means of a high-content-, high-throughput-compatible platform is useful for the 
identification of candidate ICD inducers among large chemical libraries. Nonetheless, vaccination 
assays involving immunocompetent mice and syngeneic cancer cells do not cease to constitute the 
gold-standard approach to formally identify bona fide triggers of ICD. 
Paradoxically, the major obstacle to the identification and development of clinically relevant ICD 
inducers appears to be represented by the murine system itself, as rodent and human cells do not 
necessarily respond to a specific stimulus in a comparable fashion. As a standalone example, mouse 
cells are highly resistant to the cytotoxic activity of cardiac glycosides, owing to the expression of a 
mutated subunit of their target, the Na2+/K+ ATPase.95,277 This implies that formally determining 
whether a given intervention provokes ICD in the human system is complicated. Humanized rodent 
models, i.e., immunodeficient mice reconstituted with a human immune system,278 may partially 
circumvent this issue. However, the interaction between human immune cells and the murine 
microenvironment may be negatively influenced by inter-species molecular variations that 
compromise the ability of the former to mount an appropriate immune response.279,280 Thus, 
although attempts are being made to limit such variations,281 experimental models that allow for the 
proper evaluation of ICD in the human system require further improvements. Finally, the procedure 
outlined above for the identification of novel ICD inducers assesses the biochemical processes that 
are required for the immunogenicity of anthracycline-induced cell death. However, ICD might exist 
in functionally distinct variants, implying that hitherto uncharacterized mechanisms might render 
cell death immunogenic. This possibility should be actively investigated in future studies. 
Irrespective of these caveats, we are confident that the screening of large chemical or small-
interfering RNA libraries combined with vaccination assays in the murine model will allow for the 
identification of novel, therapeutically relevant interventions for the induction or modulation of 
ICD. Moreover, the immunohistochemical detection of ICD-associated biomarkers in bioptic 
specimens from cancer patients may convey robust predictive or prognostic indications, at least 
under some circumstances.282,283 The implementation of well-designed, longitudinal 
immunomonitoring procedures into the clinical development of antineoplastic agents is required to 
ascertain the actual prognostic or predictive value of ICD-associated processes among oncological 
patients.284-286 Of note, a phase I clinical study has recently been launched to investigate the safety 
and preliminary therapeutic efficacy of adenoviral vectors genetically modified to trigger ICD, in 
subjects with malignant glioma and glioblastoma multiforme (NCT01811992). In this setting, 
serotype 5, replication-defective, first-generation adenoviruses encoding the HSV-1 thymidine 
kinase and similar vectors coding for FLT3LG are co-infused at the time of surgical tumor 
resection, followed by valacyclovir (a gancylovir-like prodrug converted by the viral thymidine 
kinase and cellular kinases into its triphosphate cytotoxic variant)287,288 in the context of current 
standard-of-care therapy (source https://clinicaltrials.gov/). The results of such a first-in-man study 
relying on the genetic induction of ICD in cancer patients are urgently awaited. 
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Legends to Figures 
Figure 1. Molecular and cellular mechanisms of immunogenic cell death. Cancer cells succumb 
to specific stimuli (e.g., anthracyclines, oxaliplatin, some forms of radiation therapy, photodynamic 
therapy) while emitting a spatiotemporally ordered combination of damage-associated molecular 
patterns (DAMPs). These signals include (but are not limited to) the pre-apoptotic exposure of the 
endoplasmic reticulum chaperone calreticulin (CALR) on the surface of dying cells, the secretion of 
ATP during the blebbing phase of apoptosis, and the release of the nuclear protein high mobility 
group box 1 (HMGB1) upon plasma membrane permeabilization. Upon binding to specific 
receptors, immunogenic cell death (ICD)-associated DAMPs promote the recruitment of antigen-
presenting cells (APCs) and stimulate their ability to take up particulate material and cross-present 
exogenous antigens to CD8+ cytotoxic T lymphocytes (CTLs) while secreting interleukin (IL)-1β. 
The consequent adaptive immune response also involves γδ T lymphocytes that produce IL-17. 
Both γδ T cells and αβ CTLs mediate direct antineoplastic effects by secreting interferon γ (IFNγ) 
and via the granzyme-perforin pathway. In addition, some CTLs acquire a memory phenotype, 
underlying the establishment of long-term immunological protection. 
Figure 2. Assays for the evaluation of immunogenic cell death in vivo. A. Vaccination assays. 
Murine cancer cells of choice are exposed in vitro to a putative inducer of immunogenic cell death 
(ICD), 1 μM mitoxantrone (positive control) or 50 μM cisplatin (negative control) for a 
predetermined time (normally 6-24 hours), then washed, resuspended in PBS, and eventually 
injected s.c. into one flank (vaccination site) of immunocompetent syngeneic mice (ideally 5-10 per 
group). One week later, mice are challenged with living cancer cells of the same type, which are 
inoculated s.c. into the contralateral flank (challenge site). Tumor incidence and growth are 
routinely monitored at both injection sites over a 1-2 months period. The development of neoplastic 
lesions at the vaccination site indicates that the stimulus under investigation is unable to cause cell 
death (under the circumstances under investigation) to a degree that is compatible with the 
elicitation of adaptive immunity. Conversely, in the absence of tumors at the vaccination site, the 
ability of the experimental maneuver under evaluation to promote bona fide ICD inversely 
correlates with the number of neoplastic lesions developed at the challenge site. As an indication, 
neoplastic cells exposed in vitro to 1 μM mitoxantrone for 6 hours and maintained in culture for 
additional 18 hours vaccinate approximately 80% of mice against a challenge with living cells of 
the same type. B. Therapeutic assays. Immunocompetent and immunodeficient syngeneic mice 
bearing grafted, genetically-driven or chemically-induced subcutaneous or orthotopic tumors are 
treated with a putative ICD inducer, mitoxantrone (positive control) or cisplatin (negative control) 
at therapeutic doses, followed by the monitoring of tumor size over a 1-3 weeks period. In this 
setting, bona fide ICD inducers mediate optimal antineoplastic effects in immunocompetent, but not 
in immunodeficient, mice. Since this is also the case of therapeutic interventions that exert off-
target immunostimulatory effects, this assay cannot be employed alone to discriminate between 
ICD and non-immunogenic cell death (nICD). Please note that all curves represented in this figure 
do not depict primary data but have been created for the sake of exemplification.  
Table 1. Assays for the detection of immunogenic cell death-associated processes in vitro. 
Process Parameter Platform Main advantage Main disadvantage Notes 
Cell death 
BAX activation 
Flow cytometry 
Fluorescence microscopy 
Immunoblotting 
Compatible with 
real-time detection 
Real-time detection requires 
transgenic cell lines 
Based on conformation-specific antibodies or 
cell lines expressing GFP-tagged BAX 
Δψm dissipation 
Flow cytometry 
Fluorescence microscopy 
Fluorometry 
Early process in the cascade 
of events leading to cell death 
The Δψm can be dissipated  
in the course of cell 
death-unrelated processes 
Several Δψm-sensitive probes with different 
spectral and biochemical properties are 
available, including DiOC(3) and CMTMRos 
Caspase activation 
Flow cytometry 
IF microscopy 
Fluorescence microscopy 
Fluorometry 
Immunoblotting 
Directly involved 
in CALR exposure 
Some caspases get activated 
in the course of cell 
death-unrelated processes 
Antibodies specific for active caspases or 
their substrates, as well as self-quenched 
peptides that emit upon cleavage are available 
Nuclear pyknosis Fluorescence microscopy 
Compatible with 
simultaneous assessments 
Prone to underestimation, 
owing to the detachment 
of cells from the substrate 
Based on chromatinophilic dyes 
like Hoechst 33342 or cell lines 
expressing RFP-tagged variants of H2B 
PMP 
Flow cytometry 
Fluorescence microscopy 
Light microscopy 
Straightforward and very 
reliable indicator of cell death 
End-stage measurement 
Several exclusion dyes with 
different spectral properties are available, 
including trypan blue, DAPI and PI 
Surface-exposed PS 
Flow cytometry 
Fluorescence microscopy 
Compatible with 
simultaneous assessments 
PS exposure does not 
always accompany cell death 
Based on fluorochrome-tagged 
variants of the protein annexin A5 
CALR exposure 
Surface-exposed 
CALR 
Flow cytometry 
Fluorescence microscopy 
Native gels 
Compatible with real- 
time detection and 
simultaneous assessments 
Real-time detection requires 
transgenic cell lines 
Based on CALR-specific antibodies, cell 
lines expressing HaloTag™-tagged CALR 
variants, GFP-tagged CALR variants, or GFP-
tagged PDIA3 variants, or the quantification 
of cell surface proteins upon biotinylation 
ER stress 
Phosphorylation of 
EIF2A or EIF2A kinases 
IF microscopy 
Immunoblotting 
EIF2A phosphorylation is 
required in CALR exposure 
Incompatible with high-
throughput platforms 
Based on phosphoneoepitope- 
specific antibodies 
XBP1 splicing Fluorescence microscopy 
Compatible with 
real-time detection 
Incomplete assessment of 
the ER stress response 
Based on cell lines expressing 
a fluorescent variant of XBP1 
ATF6 activation  Fluorescence microscopy Compatible with 
real-time detection 
Incomplete assessment of 
the ER stress response 
Based on cell lines expressing 
a fluorescent variant of ATF6 
Formation of stress 
granules 
Fluorescence microscopy Compatible with 
real-time detection 
Not specific for ER stress Based on cell lines stably expressing 
a GFP-tagged variant of G3BP1 
ATP secretion  
Extracellular ATP Luminometry 
HPLC-MS 
Very sensitive and compatible 
with real-time detection 
Extracellular ATP is exposed to 
several ectonucleotidases 
Extracellular ATP can be monitored 
in culture supernatants or in cells stably 
expressing luciferase on their surface 
Cytosolic ATP 
Fluorescence microscopy 
Luminometry 
HPLC-MS 
Cytosolic ATP is more stable 
than its extracellular counterpart 
Indirect indication 
of ATP secretion  
Residual cytosolic ATP can be monitored 
upon cell lysis or in cells expressing 
ATP-sensitive FRET-based probes 
Vesicular ATP Flow cytometry 
Fluorescence microscopy 
Compatible with 
real-time detection 
Indirect indication 
of ATP secretion  
Based on the fluorescent 
probe quinacrine  
Autophagy 
Autophagosome 
formation 
Fluorescence microscopy 
Immunoblotting 
Other techniques 
Can be monitored with a 
large panel of techniques 
Autophagy is not always 
required for the secretion of 
ATP in the course of ICD 
Cell lines stably expressing GFP-LC3 
offer a means to monitor the formation 
of autophagic vacuoles in real-time 
HMGB1 release 
Extracellular HMGB1 
ELISA 
Immunoblotting 
Mass spectroscopy 
Very sensitive and compatible 
with real-time detection 
Relatively expensive ELISA kits for the detection of HMGB1 
are available from commercial providers 
Intracellular HMGB1 Fluorescence microscopy 
Immunoblotting 
Compatible with 
real-time detection 
Indirect indication 
of HMGB1 release 
Based on HGMB1-specific antibodies 
or cell lines expressing 
fluorescent variants of HMGB1 
 
Abbreviations: ATF6, activating transcription factor 6; BAX, BCL2-associated X protein; CALR, calreticulin; CMTMRos, chloromethyltetramethylrosamine; Δψm, mitochondrial 
transmembrane potential; DAPI, 4',6-diamidino-2-phenylindole; DiOC(3), 3,3’-dihexyloxacarbocyanine iodide; EIF2A, eukaryotic translation initiation factor 2A; ELISA, enzyme-
linked immunosorbent assay; ER, endoplasmic reticulum; FRET, fluorescence resonance energy transfer; G3BP1, GTPase activating protein (SH3 domain) binding protein 1; GFP, 
green fluorescence protein; H2B, histone 2B; HGMB1, high mobility group box 1; HPLC, high-performance liquid chromatography; ICD, immunogenic cell death; IF, 
immunofluorescence; MS, mass spectrometry; PDIA3, protein disulfide isomerase family A, member 3; PI, propidium iodide; PMP, plasma membrane permeabilization; PS, 
phosphatidylserine; RFP, red fluorescent protein; XBP1, X-box binding protein 1. 


